Clinical trial · Interventional
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
A Phase 1 Study of Cosibelimab (TG-1501) in Subjects With Relapsed or Refractory Lymphoma
NCT03778073CI-TRIAL-00060471terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Strategic/Business Decision
Summary
Brief summary (as posted)
Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| B-cell Non Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Richter's Transformation | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cosibelimab | Drug | — | UNRESOLVED |
| Cosibelimab + Ublituximab + Bendamustine combination | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Cohort A
- description
- Cosibelimab (TG-1501) single-agent
- interventionNames
- Drug: Cosibelimab
- type
- EXPERIMENTAL
- label
- Cohort B
- description
- Cosibelimab + Ublituximab + Bendamustine combination
- interventionNames
- Drug: Cosibelimab + Ublituximab + Bendamustine combination
- type
- EXPERIMENTAL
- label
- Cohort C
- description
- Cosibelimab + Ublituximab + Bendamustine combination
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Key Inclusion Criteria: * Histologically confirmed relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). * Measurable disease and adequate organ function as specified in the protocol Key Exclusion Criteria: * Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or prior therapy with bendamustine. * Subjects receiving cancer therapy or investigational drug within 21 days of Cycle 1 Day 1. * Prior autologous stem cell transplant within 3 months * Active Hepatitis B or Hepatitis C
References
Publications (0)
Data not yet available
No reference posted for this study.